Brenner, R.; Edri, H.T.F.; Rouvinov, K.; Shani Shrem, N.; Meirovitz, A.; El-Saied, S.; Berezhnov, I.; Ievko, A.; Turaieva, S.; Fenig, S.;
et al. Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma. Medicina 2026, 62, 882.
https://doi.org/10.3390/medicina62050882
AMA Style
Brenner R, Edri HTF, Rouvinov K, Shani Shrem N, Meirovitz A, El-Saied S, Berezhnov I, Ievko A, Turaieva S, Fenig S,
et al. Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma. Medicina. 2026; 62(5):882.
https://doi.org/10.3390/medicina62050882
Chicago/Turabian Style
Brenner, Ronen, Hanna T. Frumin Edri, Keren Rouvinov, Noa Shani Shrem, Amichay Meirovitz, Sabri El-Saied, Ilia Berezhnov, Anna Ievko, Sofiia Turaieva, Shlomit Fenig,
and et al. 2026. "Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma" Medicina 62, no. 5: 882.
https://doi.org/10.3390/medicina62050882
APA Style
Brenner, R., Edri, H. T. F., Rouvinov, K., Shani Shrem, N., Meirovitz, A., El-Saied, S., Berezhnov, I., Ievko, A., Turaieva, S., Fenig, S., Abu Yasin, N., Fenig, E., Hussany, S., Yakobson, A., & Shalata, W.
(2026). Optimal Duration of Adjuvant Platinum–Etoposide in High-Risk Merkel Cell Carcinoma. Medicina, 62(5), 882.
https://doi.org/10.3390/medicina62050882
